Notice bibliographique
- Notice
000 nam 22 3 450
001 FRBNF446413410000006
010 .. $a 9780387236049
035 .. $a OCoLC57557318
100 .. $a 20170801d2005 m y0engy50 ba
101 0. $a eng
102 .. $a US
105 .. $a a z 00|y|
106 .. $a s $a z
135 .. $a dou||||||||||
181 .0 $6 01 $a i $b xxxe
181 .. $6 02 $c txt $2 rdacontent
182 .0 $6 01 $a b
182 .. $6 02 $c c $2 rdamedia
200 1. $a Selective sentinel lymphadenectomy for human solid cancer $b Texte électronique $f edited by Stanley P.L. Leong, Yuko Kitagawa, Masaki Kitajima
210 .. $a New York $c Springer $d cop. 2005
215 .. $a 1 ressource dématérialisée
225 1. $a Cancer treatment and research
300 .. $a Includes bibliographical references and index
330 .. $a Lymph node (LN) status is the most important prognostic indicator for the clinical
outcome of patients in human solid cancer. Recent developments in sentinel lymph node
(SLN) concept and technology have resulted in the application of this revolutionary
approach to determine if cancer has metastasized. The underlying thesis in solid cancer
biology is that metastasis generally starts in an orderly progression, often spreading
through the lymphatic channels to the SLN. Thus, the logical approach is to harvest
that specific sLN for thorough analysis. The mist exciting possibility of selective
sentinel lymphadenectomy (SSL) is that it will lead to early diagnosis of micrometastasis
in regional LNs. New molecular and genetic tools may be used to dissect the mechanisms
of lymphatic and hemotogenous routes of metastasis. If such mechanisms can be understood,
new therapeutic advances may be developed to prevent the process of micrometastasis
676 .. $a 616.994 46 $v 23
801 .3 $a US $b OCoLC $c 20170801 $h 57557318 $2 marc21
801 .0 $b DNLM/DLC
930 .. $5 FR-759999999:44641341001001 $a ACQNUM-23107 $b 759999999 $c Document numérisé $d N
